Kiniksa Pharmaceuticals to Present at 2022 Wedbush PacGrow Healthcare Conference
August 03, 2022 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that its management will participate in a fireside chat at the 2022 Wedbush PacGrow...
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 03, 2022 07:30 ET
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) net revenue of $27.0 million in Q2 2022 – – ARCALYST full-year 2022 net revenue expected to be $115 - $130 million – – Upfront and near-term proceeds of $100 million...
Kiniksa Pharmaceuticals Announces Global License Agreement with Genentech for Vixarelimab
August 03, 2022 07:29 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Kiniksa to receive $100 million in upfront and near-term payments – – Kiniksa is eligible to receive development and commercial milestones as well as royalties on net sales – – Global license...
Kiniksa Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022
August 02, 2022 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Wednesday, August 3, 2022,...
Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 03, 2022 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) net revenue of $22.2 million in Q1 2022 – – ARCALYST full-year 2022 net revenue expected to be $115 - $130 million – – Cash reserves expected to fund operations into at...
Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results on May 3, 2022
May 02, 2022 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, May 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 3, 2022, at 8:30...
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
February 22, 2022 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
– ARCALYST® (rilonacept) net revenue of $18.7 million in Q4 2021 and $38.5 million in 2021 –– ARCALYST collaboration achieved profitability in Q4 2021 –– ARCALYST full-year 2022 net revenue expected...
Kiniksa Pharmaceuticals and Huadong Medicine Announce Strategic Collaboration
February 22, 2022 07:59 ET
|
Kiniksa Pharmaceuticals, Ltd.
– Collaboration includes rights to develop and commercialize ARCALYST® and mavrilimumab in the Asia Pacific Region (excluding Japan) – – Kiniksa to receive $22 million upfront; eligible to receive...
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on February 22, 2022
February 18, 2022 16:01 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 22, 2022,...
Kiniksa Provides Corporate Update and Outlines Anticipated 2022 Milestones
January 10, 2022 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
- ARCALYST® full-year 2022 guidance to be provided with Q4 2021 financial results -- Vixarelimab Phase 2b data in prurigo nodularis expected in 2H 2022 –- KPL-404 Phase 2 trial in rheumatoid arthritis...